The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
December 4, 2017
View Complete Issue         Table of Contents 2019 
Three More Immune Checkpoint Inhibitors for Advanced Bladder Cancer (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Three More Immune Checkpoint Inhibitors for Advanced Bladder Cancer (online only)
December 4, 2017 (Issue: 1535)
The FDA has approved avelumab (Bavencio – EMD Serono) and durvalumab (Imfinzi – AstraZeneca), two new immune check point inhibitors, and pembrolizumab (Keytruda – Merck), a checkpoint inhibitor that has been available in the US since 2014,...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Three More Immune Checkpoint Inhibitors for Advanced Bladder Cancer (online only)
Article code: 1535f
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.